HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Intrathecal injection of adenosine 2A receptor agonists reversed neuropathic allodynia through protein kinase (PK)A/PKC signaling.

Abstract
A single intrathecal dose of adenosine 2A receptor (A2AR) agonist was previously reported to produce a multi-week reversal of allodynia in a chronic constriction injury (CCI) model of neuropathic pain. We aimed to determine if this long-term reversal was induced by A2AR agonism versus more generalized across adenosine receptor subtypes, and begin to explore the intracellular signaling cascades involved. In addition, we sought to identify whether the enduring effect could be extended to other models of neuropathic pain. We tested an A1R and A2BR agonist in CCI and found the same long duration effect with A2BR but not A1R agonism. An A2AR agonist (ATL313) produced a significant long-duration reversal of mechanical allodynia induced by long established CCI (administered 6 weeks after surgery), spinal nerve ligation and sciatic inflammatory neuropathy. To determine if ATL313 had a direct effect on glia, ATL313 was coadministered with lipopolysaccharide to neonatal microglia and astrocytes in vitro. ATL313 significantly attenuated TNFα production in both microglia and astrocytes but had no effect on LPS induced IL-10. Protein kinase C significantly reversed the ATL313 effects on TNFα in vitro in microglia and astrocytes, while a protein kinase A inhibitor only effected microglia. Both intrathecal PKA and PKC inhibitors significantly reversed the effect of the A2AR agonist on neuropathic allodynia. Therefore, A2AR agonists administered IT remain an exciting novel target for the treatment of neuropathic pain.
AuthorsLisa C Loram, Frederick R Taylor, Keith A Strand, Jacqueline A Harrison, Rachael Rzasalynn, Paige Sholar, Jayson Rieger, Steven F Maier, Linda R Watkins
JournalBrain, behavior, and immunity (Brain Behav Immun) Vol. 33 Pg. 112-22 (Oct 2013) ISSN: 1090-2139 [Electronic] Netherlands
PMID23811314 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S.)
CopyrightCopyright © 2013 Elsevier Inc. All rights reserved.
Chemical References
  • ATL 313
  • Adenosine A2 Receptor Agonists
  • Piperidines
  • Cyclic AMP-Dependent Protein Kinases
  • Protein Kinase C
Topics
  • Adenosine A2 Receptor Agonists (administration & dosage, therapeutic use)
  • Animals
  • Cells, Cultured
  • Chronic Disease
  • Constriction, Pathologic (drug therapy, enzymology, pathology)
  • Cyclic AMP-Dependent Protein Kinases (antagonists & inhibitors, physiology)
  • Hyperalgesia (enzymology, metabolism, pathology)
  • Inflammation (drug therapy, enzymology, pathology)
  • Injections, Spinal
  • Ligation
  • Male
  • Piperidines (administration & dosage, therapeutic use)
  • Protein Kinase C (antagonists & inhibitors, physiology)
  • Random Allocation
  • Rats
  • Rats, Sprague-Dawley
  • Sciatic Neuropathy (drug therapy, enzymology, pathology)
  • Signal Transduction (drug effects, immunology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: